| 12.66 -0.305 (-2.35%) | 07-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.31 | 1-year : | 19.69 |
| Resists | First : | 14.82 | Second : | 16.86 |
| Pivot price | 12.9  |
|||
| Supports | First : | 11.52 | Second : | 9.58 |
| MAs | MA(5) : | 13.32 |
MA(20) : | 12.79 |
| MA(100) : | 16.65 |
MA(250) : | 33.5 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 32.7 |
D(3) : | 45 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 98 | Low : | 10.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KRRO ] has closed above bottom band by 41.1%. Bollinger Bands are 65% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.31 - 13.37 | 13.37 - 13.44 |
| Low: | 12.45 - 12.52 | 12.52 - 12.58 |
| Close: | 12.86 - 12.96 | 12.96 - 13.07 |
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Sat, 05 Jul 2025
We're Keeping An Eye On Korro Bio's (NASDAQ:KRRO) Cash Burn Rate - simplywall.st
Sun, 29 Jun 2025
Korro Bio, Inc.(NasdaqCM: KRRO) dropped from Russell Small Cap Comp Growth Index - MarketScreener
Thu, 08 May 2025
Korro lays off 20% of staff to fund genetic med trials, Novo Nordisk partnership - Fierce Biotech
Wed, 16 Apr 2025
Chardan sets $25 target on Korro Bio stock with Buy rating - Investing.com
Tue, 01 Apr 2025
RNA-Editing Pioneer Korro Bio Lands Elite CSO with 20+ Drug Development Success Record - Stock Titan
Fri, 28 Mar 2025
Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 104.4 (%) |
| Shares Short | 926 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -9.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.8 |
| Profit Margin | 0 % |
| Operating Margin | -981.2 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -60.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -9.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | 0.85 |
| Price to Sales | 24.66 |
| Price to Cash Flow | -1.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|